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Introduction Currently three drugs have been approved by the federal drug administration to treat alcoholism: Revia (Naltrexone [NTX] , a non-selective opioid antagonist), Campral (acamprosate, a NMDA receptor antagonist), and Antabuse (Disulfiram, an inhibitor of acetylaldehyde dehydrogenase). While these drugs can be efficacious in reducing ethanol consumption, all have clinical limitations and suffer from compliance issues (Pettinati et al., 2000; Buonopane and Petrakis, 2005; Anton et al., 2006; Swift, 2007; Garbutt, 2009; Mitchell et al., 2009) . One of the drugs currently in clinical trials to treat alcoholism is the neurokinin (NK1) receptor antagonist LY686017. It is thought that the efficacy of this drug is due, at least in part, to the reduction of anxiety and craving in anxious alcoholdependent subjects (George et al., 2008; Heilig et al., 2009 ). According to the National Institute of Mental Health, approximately 40 million US American adults suffer from an anxiety disorder [AD] . The individual and societal cost associated with ADs is extremely high (Wittchen, 2002; Hoffman et al., 2008) . Importantly, people suffering from ADs are more susceptible to substance abuse (Wittchen, 2002; Hoffman et al., 2008) . Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines (BZDs) are the two classes of drug most commonly used to treat ADs (Cloos and Ferreira, 2009) . SSRIs are generally well-tolerated; however, they take several weeks to take effect, and each SSRI is only effective in a minority of patients (Simon, 2001) , who cannot be identified prior to initiating treatment; (Tiwari et al., 2009) . BZDs are commonly prescribed to control anxiety "attacks;" however, they themselves are intoxicating and habit-forming (Isbister et al., 2004; O'Brien C, 2005) . Importantly, BZDs can increase the palatability of ethanol and increase alcohol consumption (Soderpalm and Hansen, 1998) . Thus, there is This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 6, 2010 as DOI: 10.1124/jpet.110.170969 at ASPET Journals on April 12, 2017 jpet.aspetjournals.org Downloaded from JPET #170969 6 significant need for novel targets and treatments for ADs, especially for anxiety that is co-morbid with alcoholism.
One target that is linked to anxiety is the delta opioid receptor (DOR). Disruption of the gene encoding DOR or its endogenous ligand produces an anxious-like phenotype in mice (Filliol et al., 2000; Ragnauth et al., 2001; Roberts et al., 2001) , suggesting that DOR agonists could be anxiolytic. The DOR is a particularly interesting target for anxiety, because it has also been found to regulate ethanol consumption. In some cases mice disrupted for DOR show enhanced ethanol consumption when alcohol naïve (van Rijn and Whistler, 2009 ), but DOR knock out mice also show enhanced drinking and preference for alcohol once they have been drinking for some time (Roberts et al., 2001 ).
Importantly, two DOR subtypes (DOR1 and DOR2) can be distinguished in vivo (Mattia et al., 1991; Zaki et al., 1996) , and recently we found that these subtypes have opposing effects with regard to ethanol intake (van Rijn and Whistler, 2009).
As mentioned above, there is significant co-morbidity between anxiety and alcohol abuse, and anxiety and stress are risk factors that predispose an individual to both the primary development of alcoholism as well as relapse in withdrawing and abstinent patients. Individuals abstaining from ethanol may experience increased levels of anxiety, especially within the first 24-48 hours after their last drink, a phenomenon generally known as the alcohol withdrawal syndrome. This is often treated with benzodiazepines (McKeon et al., 2008) . Stress-related-anxiety-induced relapse can also be modeled in preclinical animal models, as rats subjected to a foot shock paradigm, for example, show increased relapse to alcohol (Le et al., 1999; Liu and Weiss, 2003) . As would be expected if activity at the DOR were anxiolytic, rats that express more functional DORs show less This article has not been copyedited and formatted. The final version may differ from this version.
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Here, we investigate the ability of DOR selective agonists to decrease ethanol consumption and both anxiety-and ethanol withdrawal-induced anxiety-like behaviors compared with drugs (NTX and diazepam) currently available to treat these disorders.
We find that the selective DOR agonist SNC80 reduces anxiety-like behaviors, but also increases ethanol consumption. In comparison, the DOR1-selective agonist TAN-67, which we had previously shown to decrease ethanol intake (van Rijn and Whistler, 2009 ), has no effect on anxiety-like behavior in alcohol naïve mice. Interestingly however, we observe that TAN-67 does reduce ethanol withdrawal-induced anxiety-like behaviors. In contrast, we find that two drugs, commonly used in the treatment of alcoholism (NTX) or anxiety (diazepam), may induce anxiogenic-like behavior and have limited ability to decrease ethanol consumption, respectively. Therefore, DOR1 subtype-selective drugs may potentially have an improved ability to simultaneously reduce ethanol intake and anxiety associated with ethanol abstinence than the currently available therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version. Chronic ethanol exposure. The limited access two-bottle choice paradigm was performed as previously described (van Rijn and Whistler, 2009 ). In short, for the ethanol exposure, mice were individually housed in ventilated plexiglass cages at ambient temperature (21ºC) in a room maintained on a reversed 12L:12D cycle (lights off at 10.00, lights on at 22.00). Food and water was provided ad libitum. The mice were given one week to acclimatize to the individual housing conditions and reverse light cycle before the start of the experiments. A two-bottle, limited access (4 hours/day), drinking paradigm was employed for one week (5 days). During the limited drinking phase mice had access to water and either a 10% ethanol solution or a 2% sucrose solution.
Anxiety-like behavior measurements
This article has not been copyedited and formatted. The final version may differ from this version. Ethanol-withdrawal-induced anxiety. To study ethanol withdrawal-induced anxietylike behaviors, mice were trained in the limited access two-bottle choice paradigm for 5 days. On day 6 (24 hour after the last access to ethanol or sucrose), anxiety levels in the withdrawn mice were tested using the elevated plus maze and the dark-light transition box.
Data analysis.
Baseline values for the ethanol drinking studies were determined by taking the average of the consumption over the three days prior to injection. Statistical analysis was performed using Prism software (GraphPad, San Diego, CA). Significance was determined by means of student t-test, one-way ANOVA or two-way ANOVA (repeated measures). A post-hoc Newman-Keuls (one-way ANOVA) or Bonferroni (twoway ANOVA) test was used when a significant overall effect was found (p<0.05). (*, p<0.05; **, p<0.01; ***, p<0.001).
Drugs. Ethanol solutions were prepared in tap water using 95% (vol/vol) ethanol (Gold Shield Chemical Co., Hayward, CA, USA) (±)-SB205607 dihydrobromide (TAN-67, 25 mg/kg) was purchased from Tocris (MO, USA). Sucrose, naltrexone (NTX, 1 mg/kg), SNC80 (20 mg/kg), and diazepam (1 & 3 mg/kg) were purchased from Sigma-Aldrich (MO, USA). All compounds were dissolved in saline. Diazepam was suspended in solution with 0.06% Tween 80. This concentration of Tween has no effect on behavior (Supplemental Figure 1A and B) and, therefore, we used saline as vehicle in all our experiments to allow comparison across all treatment groups. All drugs were prepared This article has not been copyedited and formatted. The final version may differ from this version. 13 pharmacological specificity of the DOR1 agonist TAN-67 was critical for its ability to reduce ethanol consumption. Naltrexone (NTX) the current FDA-approved drug used in the treatment of alcoholism can also decrease ethanol consumption in mice ((van Rijn and Whistler, 2009) , and see Figure 2C and 2D), but also decreased water consumption and therefore did not effect preference ( Figure 2D ). In addition, the ability of NTX to antagonize all three opioid receptors (Raynor et al., 1994) in not unusual for this strain of mice (Griebel et al., 2000; Lepicard et al., 2000; Carola et al., 2002; Lalonde and Strazielle, 2008) . Additionally, it is not uncommon for 1 mg/kg diazepam to fail to reduce anxiety in C57Bl/6 mice in the elevated plus maze paradigm (Griebel et al., 2000; Lepicard et al., 2000) . Interestingly, we found that mice treated with Figure 3D ). This suggests that NTX may elicit some anxiety like behavior even in alcohol naïve mice, which is in agreement with previous reports that have shown that in some cases NTX can increase anxiety (King et al., 1997; Maremmani et al., 1998; Kozak et al., 2007) . Thus, we find the light dark transition box appears to be the more sensitive assay for detecting anxiolytic-like effects while the elevated plus maze appears to be more sensitive for detecting anxiogenic-like effects, at least for C57BL/6 mice. The changes in anxiety-like behavior were unlikely due to changes in general locomotion, as neither ethanol nor sucrose withdrawal had a significant effect on locomotor activity [F(2,31) = 1.14, p=.33] ( Figure 4D ).
DOR selective agonists attenuate ethanol withdrawal induced anxiety-like behavior.
We next examined whether DOR-selective agonists could decrease ethanol-withdrawalinduced anxiety-like behavior. We found that SNC80 significantly reduced withdrawal- Figure 5D ). Benzodiazepines and ethanol both allosterically activate GABA A receptors. Thus, the reduction in efficacy of diazepam in the ethanol withdrawn mice could reflect "cross tolerance" at this target as a function of decreased number or function of GABA A -receptors as a consequence of alcohol exposure (Sanna et al., 2003) . To examine this possibility, we tested whether a higher dose of could overcome the apparent tolerance. However, 3 mg/kg, diazepam produced significant sedative effects, immobilizing mice (Supplemental Figure 1C) . 
Discussion
Here we show that some but not all DOR subtype selective ligands show dual efficacy at reducing ethanol consumption and ethanol withdrawal induced anxiety. We and others have previously reported that DOR KO mice consume more ethanol and show increased anxiety-like behavior than wild-type mice (Roberts et al., 2001; van Rijn and Whistler, 2009) (Filliol et al., 2000) . Together these studies suggest that DORs play a role in both anxiety and drinking behavior. Anxiety is a key risk factor for relapse in human alcoholics, which has led to the use of anxiolytics as adjunct therapy in the treatment of alcoholism. However, here we found that anxiolytics, including the benzodiazepine diazepam and the DOR-selective agonist SNC80, while reducing anxiety like behaviors, increase rather than decrease drinking. Importantly, we found that the DOR1-selective agonist TAN-67, which showed no effect on anxiety like behaviors in alcohol naïve mice, reduced both drinking and alcohol withdrawal induced anxiety.
We hypothesize that the diversity in the effectiveness of distinct opioid drugs for ethanol consumption and anxiety, can be attributed to the existence of multiple receptor subtypes that differentially effect behavior. Two pharmacologically distinct DOR 18 SNC80 decreases anxiety-like behaviors (Saitoh et al., 2004) , and that the DOR selective antagonist naltrindole (Perrine et al., 2006) and the DOR2-subtype selective antagonist naltriben produce an anxiogenic-like effect in the elevated plus maze in rats (Saitoh et al., 2005) . However, although it decreases anxiety, SNC80 increases alcohol consumption.
Thus, it appears that decreasing anxiety per se does not lead to a decrease in ethanol consumption. Importantly, we found that, unlike SNC80 (and diazepam), the DOR1 agonist TAN-67 decreased ethanol consumption. Although TAN-67 was not anxiolytic in alcohol naïve mice, it eliminated alcohol-withdrawal induced anxiety. Thus TAN-67 is distinguished from SNC80 (and diazepam) in that it reduces rather than enhances drinking and has a selective effect on alcohol-withdrawal induced anxiety. SNC80 and TAN-67 are both highly selective for DOR over MOR (Knapp et al., 1995; Knapp et al., 1996) . However, the dextrorotary enantiomer of TAN-67 has been shown to interact with spinal nociceptin/orphanin FQ receptor with nanomolar affinity (Kamei et al., 1999) .
Further studies are required to determine to what degree, if any, the racemic mixture of TAN-67 or the dextrorotary enantiomer affect ethanol consumption and anxiety through the nociceptin receptor. Our finding that TAN-67 shifts from being ineffective in reducing anxiety-like behavior in naïve mice to having anxiolytic properties in ethanol withdrawn mice, corresponds to findings that DORs may be upregulated after chronic stress and ethanol consumption (Commons, 2003; Margolis et al., 2008) Benzodiazepines are a common treatment of alcohol withdrawal symptoms (McKeon et al., 2008) . Several rodent models exist that can reproduce the ethanol withdrawal-induced anxiety observed in humans. In general, the methods used to induce ethanol dependence require forced exposure to the ethanol, such as ethanol containing liquid diets, ethanol vapor chambers and intra peritoneal ethanol injections (Kliethermes, 2005) . The forced nature of these methods however does not reflect human behavior and may further complicate any extrapolation of data obtained in mice to the human situation. Another issue in these rodent models is that withdrawn animals often have a reduction in their locomotor activity, which could be mistaken as a sign of anxiety-like behavior (Kliethermes, 2005) . We find that, in a model of voluntary ethanol consumption, ethanolbut not sucrose-withdrawal increases the expression of anxiety-like behavior.
Importantly, the locomotor activity of these mice is not affected. Therefore, we believe this paradigm may be a suitable model to study ethanol withdrawal-induced anxiety-like behavior. Most importantly, using this model we found that both SNC80 and TAN-67 are effective in reducing ethanol withdrawal-induced anxiety-like behavior and are, in fact, more effective than diazepam.
The ability of TAN-67 to decrease ethanol withdrawal induced anxiety-like behavior is surprising as TAN-67 does not affect anxiety-like behavior in naïve mice. DOR expression has been shown to change under influence of chronic stressors, such as inflammation (Cahill et al., 2003) , and chronic exposure to morphine (Cahill et al., 2001 ), This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 6, 2010 as DOI: 10.1124 at ASPET Journals on April 12, 2017 jpet.aspetjournals.org Downloaded from ethanol (Margolis et al., 2008) and stress (Commons, 2003) . We hypothesize that drinking and/or withdrawal from ethanol, may change the number of functional DORs, in particular DOR1s. An increase in DOR function could explain our finding that both TAN-67 and SNC80 become more effective in the ethanol withdrawn mice. In particular, we would expect chronic ethanol to upregulate the number or function of DOR1s in circuits or brain regions that control anxiety. This hypothesis is supported by recent findings, that chronic ethanol exposure recruited functional DORs in the central nucleus of the amygdala (Bie et al., 2009) . Intriguingly, a recent study showed that DORs are involved in the function of benzodiazepines (Primeaux et al., 2006) . Thus a change in the number of functional DORs, induced by heavy ethanol consumption and stress, could thereby also possibly affect the efficacy of benzodiazepines.
In conclusion, we show that the current drugs available to combat alcoholism in the human population while effective at controlling individual aspects of the disease none are ideally suited to treat both consumption and withdrawal induced anxiety. Diazepam reduces anxiety-like behavior in naïve mice but increases ethanol palatability and consumption and loses efficacy as an anxiolytic after drinking. Conversely, NTX can reduce ethanol consumption, but it suffers from side effects such as dysphoria and increased pain sensitivity and may increase anxiety. Here we show that drugs that selectively target DOR subtypes could show promise as "dual efficacy" drugs to reduce both ethanol consumption and withdrawal induced anxiety. The choice of DOR subtype will be key to the success of this strategy as the DOR1-selective drug TAN-67 decreased both alcohol withdrawal-induced anxiety and consumption while the DOR agonist SNC80 decreased anxiety but increased consumption. In short, we believe that selectively 
